vs
OptimizeRx Corp（OPRX）与ROCKWELL MEDICAL, INC.（RMTI）财务数据对比。点击上方公司名可切换其他公司
OptimizeRx Corp的季度营收约是ROCKWELL MEDICAL, INC.的1.8倍（$32.2M vs $18.3M），OptimizeRx Corp净利率更高（15.6% vs -3.0%，领先18.6%），OptimizeRx Corp同比增速更快（-0.2% vs -25.6%），OptimizeRx Corp自由现金流更多（$7.1M vs $2.2M），过去两年OptimizeRx Corp的营收复合增速更高（28.0% vs -10.1%）
OptimizeRx Corp是一家总部位于美国的数字健康科技企业，为生命科学公司、医疗机构及药房合作伙伴提供患者参与、药物可负担性和临床沟通相关解决方案，核心产品包括数字购药优惠工具、患者支持项目等，助力提升药物可及性与用药依从性。
罗克韦尔医疗成立于1996年，总部位于美国密歇根州威克瑟姆，是一家上市制药企业，核心业务聚焦于终末期肾病与慢性肾病相关治疗方案的研发与商业化推广。
OPRX vs RMTI — 直观对比
营收规模更大
OPRX
是对方的1.8倍
$18.3M
营收增速更快
OPRX
高出25.4%
-25.6%
净利率更高
OPRX
高出18.6%
-3.0%
自由现金流更多
OPRX
多$4.9M
$2.2M
两年增速更快
OPRX
近两年复合增速
-10.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.2M | $18.3M |
| 净利润 | $5.0M | $-554.0K |
| 毛利率 | 74.8% | 21.1% |
| 营业利润率 | 26.6% | -2.2% |
| 净利率 | 15.6% | -3.0% |
| 营收同比 | -0.2% | -25.6% |
| 净利润同比 | 6535.9% | 26.7% |
| 每股收益（稀释后） | $0.27 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPRXRMTI
| Q4 25 | $32.2M | $18.3M | ||
| Q3 25 | $26.1M | $15.9M | ||
| Q2 25 | $29.2M | $16.1M | ||
| Q1 25 | $21.9M | $18.9M | ||
| Q4 24 | $32.3M | $24.7M | ||
| Q3 24 | $21.3M | $28.3M | ||
| Q2 24 | $18.8M | $25.8M | ||
| Q1 24 | $19.7M | $22.7M |
净利润OPRXRMTI
| Q4 25 | $5.0M | $-554.0K | ||
| Q3 25 | $779.0K | $-1.8M | ||
| Q2 25 | $1.5M | $-1.5M | ||
| Q1 25 | $-2.2M | $-1.5M | ||
| Q4 24 | $-78.0K | $-756.0K | ||
| Q3 24 | $-9.1M | $1.7M | ||
| Q2 24 | $-4.0M | $343.0K | ||
| Q1 24 | $-6.9M | $-1.7M |
毛利率OPRXRMTI
| Q4 25 | 74.8% | 21.1% | ||
| Q3 25 | 67.2% | 14.3% | ||
| Q2 25 | 63.8% | 15.6% | ||
| Q1 25 | 60.9% | 16.1% | ||
| Q4 24 | 68.1% | 14.7% | ||
| Q3 24 | 63.1% | 22.0% | ||
| Q2 24 | 62.2% | 17.6% | ||
| Q1 24 | 62.0% | 13.5% |
营业利润率OPRXRMTI
| Q4 25 | 26.6% | -2.2% | ||
| Q3 25 | 7.9% | -9.9% | ||
| Q2 25 | 10.9% | -8.4% | ||
| Q1 25 | -9.6% | -7.2% | ||
| Q4 24 | 11.2% | -2.1% | ||
| Q3 24 | -40.2% | 6.8% | ||
| Q2 24 | -19.9% | 2.0% | ||
| Q1 24 | -25.5% | -5.8% |
净利率OPRXRMTI
| Q4 25 | 15.6% | -3.0% | ||
| Q3 25 | 3.0% | -11.0% | ||
| Q2 25 | 5.2% | -9.3% | ||
| Q1 25 | -10.0% | -8.0% | ||
| Q4 24 | -0.2% | -3.1% | ||
| Q3 24 | -42.8% | 5.9% | ||
| Q2 24 | -21.3% | 1.3% | ||
| Q1 24 | -35.0% | -7.6% |
每股收益（稀释后）OPRXRMTI
| Q4 25 | $0.27 | $-0.01 | ||
| Q3 25 | $0.04 | $-0.05 | ||
| Q2 25 | $0.08 | $-0.05 | ||
| Q1 25 | $-0.12 | $-0.04 | ||
| Q4 24 | $0.00 | $-0.02 | ||
| Q3 24 | $-0.50 | $0.04 | ||
| Q2 24 | $-0.22 | $0.01 | ||
| Q1 24 | $-0.38 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $10.7M |
| 总债务越低越好 | $26.3M | — |
| 股东权益账面价值 | $128.3M | $37.0M |
| 总资产 | $176.9M | $57.1M |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资OPRXRMTI
| Q4 25 | $23.4M | $10.7M | ||
| Q3 25 | $19.5M | $13.6M | ||
| Q2 25 | $16.6M | $12.5M | ||
| Q1 25 | $16.6M | $11.4M | ||
| Q4 24 | $13.4M | $15.7M | ||
| Q3 24 | $16.1M | $12.3M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $6.6M |
总债务OPRXRMTI
| Q4 25 | $26.3M | — | ||
| Q3 25 | $28.8M | — | ||
| Q2 25 | $29.3M | — | ||
| Q1 25 | $33.8M | — | ||
| Q4 24 | $34.3M | — | ||
| Q3 24 | $36.8M | — | ||
| Q2 24 | $37.3M | — | ||
| Q1 24 | $37.8M | — |
股东权益OPRXRMTI
| Q4 25 | $128.3M | $37.0M | ||
| Q3 25 | $122.3M | $37.0M | ||
| Q2 25 | $119.3M | $30.4M | ||
| Q1 25 | $116.3M | $31.5M | ||
| Q4 24 | $117.0M | $32.6M | ||
| Q3 24 | $114.5M | $29.1M | ||
| Q2 24 | $121.0M | $23.5M | ||
| Q1 24 | $122.5M | $20.6M |
总资产OPRXRMTI
| Q4 25 | $176.9M | $57.1M | ||
| Q3 25 | $170.3M | $57.5M | ||
| Q2 25 | $169.3M | $52.6M | ||
| Q1 25 | $167.8M | $54.0M | ||
| Q4 24 | $171.2M | $59.2M | ||
| Q3 24 | $165.2M | $57.1M | ||
| Q2 24 | $172.9M | $53.0M | ||
| Q1 24 | $176.4M | $50.7M |
负债/权益比OPRXRMTI
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.31× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.1M | $2.3M |
| 自由现金流经营现金流 - 资本支出 | $7.1M | $2.2M |
| 自由现金流率自由现金流/营收 | 22.0% | 12.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.41× | — |
| 过去12个月自由现金流最近4个季度 | $18.7M | $-1.2M |
8季度趋势，按日历期对齐
经营现金流OPRXRMTI
| Q4 25 | $7.1M | $2.3M | ||
| Q3 25 | $3.2M | $-1.3M | ||
| Q2 25 | $4.6M | $1.8M | ||
| Q1 25 | $3.9M | $-3.5M | ||
| Q4 24 | $198.0K | $865.0K | ||
| Q3 24 | $1.8M | $4.3M | ||
| Q2 24 | $782.0K | $1.4M | ||
| Q1 24 | $2.1M | $-2.4M |
自由现金流OPRXRMTI
| Q4 25 | $7.1M | $2.2M | ||
| Q3 25 | $3.2M | $-1.5M | ||
| Q2 25 | $4.6M | $1.7M | ||
| Q1 25 | $3.8M | $-3.5M | ||
| Q4 24 | $181.0K | $470.0K | ||
| Q3 24 | $1.8M | $4.1M | ||
| Q2 24 | $737.0K | $1.2M | ||
| Q1 24 | $2.1M | $-2.5M |
自由现金流率OPRXRMTI
| Q4 25 | 22.0% | 12.0% | ||
| Q3 25 | 12.2% | -9.6% | ||
| Q2 25 | 15.6% | 10.5% | ||
| Q1 25 | 17.5% | -18.8% | ||
| Q4 24 | 0.6% | 1.9% | ||
| Q3 24 | 8.3% | 14.4% | ||
| Q2 24 | 3.9% | 4.5% | ||
| Q1 24 | 10.6% | -11.1% |
资本支出强度OPRXRMTI
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.1% | 0.3% | ||
| Q4 24 | 0.1% | 1.6% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.2% | 1.1% | ||
| Q1 24 | 0.2% | 0.6% |
现金转化率OPRXRMTI
| Q4 25 | 1.41× | — | ||
| Q3 25 | 4.11× | — | ||
| Q2 25 | 2.98× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPRX
暂无分部数据
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
